Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vinblastine Sulfate

FDA-approved product (injectable, injection), marketed as Velban, Vinblastine Sulfate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vinblastine Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Classic Hodgkin lymphoma
  • Fungal infectious disease
  • Hodgkins lymphoma
  • Lymphoid neoplasm
  • Lymphoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Vinca alkaloids and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis70.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vinblastine Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vinblastine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

    NCT07551583 · start 2026-08-19

    Registered record
    Registry ID
    NCT07551583
    Conditions
    Hodgkin Lymphoma
    Interventions
    Nivolumab; Doxorubicin Hydrochloride; Vinblastine; Dacarbazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-08-19
    Completion
    2032-12-31
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma
    InterventionNivolumab; Doxorubicin Hydrochloride; Vinblastine; Dacarbazine
    PhasePhase 2
    Registry statusRecruiting

  • Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

    NCT07431060 · start 2026-02-13

    Registered record
    Registry ID
    NCT07431060
    Conditions
    Langerhans Cell Histiocytosis (LCH)
    Interventions
    Prednisone; Vincristine; Mercaptopurine; Luvometinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-02-13
    Completion
    2030-12-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLangerhans Cell Histiocytosis (LCH)
    InterventionPrednisone; Vincristine; Mercaptopurine; Luvometinib
    PhaseNot applicable
    Registry statusRecruiting

  • Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

    NCT06666348 · start 2026-01-12

    Registered record
    Registry ID
    NCT06666348
    Conditions
    Pediatric Low-grade Glioma
    Interventions
    Mirdametinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-01-12
    Completion
    2033-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Low-grade Glioma
    InterventionMirdametinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

    NCT07209059 · start 2025-07-29

    Registered record
    Registry ID
    NCT07209059
    Conditions
    Hodgkin Lymphoma; Hodgkin Disease; Advanced Hodgkin Lymphoma
    Interventions
    Nivolumab; N-EACOPD-14; N-AVD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-07-29
    Completion
    2028-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma; Hodgkin Disease; Advanced Hodgkin Lymphoma
    InterventionNivolumab; N-EACOPD-14; N-AVD
    PhasePhase 2
    Registry statusRecruiting

  • Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

    NCT06358573 · start 2024-10-24

    Registered record
    Registry ID
    NCT06358573
    Conditions
    Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer
    Interventions
    INT230-6; neoadjuvant immuno-chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-24
    Completion
    2031-12
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer
    InterventionINT230-6; neoadjuvant immuno-chemotherapy
    PhasePhase 2
    Registry statusRecruiting

  • A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

    NCT06424899 · start 2024-05-19

    Registered record
    Registry ID
    NCT06424899
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    Adebrelimab; radical chemoradiotherapy; Platinum based chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-05-19
    Completion
    2027-12-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionAdebrelimab; radical chemoradiotherapy; Platinum based chemotherapy
    PhasePhase 2
    Registry statusRecruiting

  • Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

    NCT06381570 · start 2024-03-21

    Registered record
    Registry ID
    NCT06381570
    Conditions
    Low-grade Glioma
    Interventions
    Tovorafenib; Vinblastine
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2024-03-21
    Completion
    2029-03-21
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-grade Glioma
    InterventionTovorafenib; Vinblastine
    PhaseEarly phase 1
    Registry statusRecruiting

  • H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis

    NCT00488605 · start 2023-08-01

    Registered record
    Registry ID
    NCT00488605
    Conditions
    Leukemia
    Interventions
    Prednisone, Vinblastin, 6-mercaptopuroine; Leucovorin, Methotrexate, Vinblastine, Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2023-08-01
    Completion
    2023-08-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionPrednisone, Vinblastin, 6-mercaptopuroine; Leucovorin, Methotrexate, Vinblastine, Prednisone
    PhasePhase 3
    Registry statusWithdrawn

  • A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    NCT05675410 · start 2023-05-11

    Registered record
    Registry ID
    NCT05675410
    Conditions
    Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
    Interventions
    Biospecimen Collection; Bleomycin Sulfate; Brentuximab Vedotin; Computed Tomography; Cyclophosphamide; Dacarbazine; Doxorubicin Hydrochloride; Etoposide; Etoposide Phosphate; Fludeoxyglucose F-18; Involved-site Radiation Therapy; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography; Prednisolone; Prednisone; Procarbazine Hydrochloride; Questionnaire Administration; Vinblastine Sulfate; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-05-11
    Completion
    2031-04-28
    Enrolment
    1,875

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
    InterventionBiospecimen Collection; Bleomycin Sulfate; Brentuximab Vedotin; Computed Tomography +16 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

    NCT04576117 · start 2021-02-16

    Registered record
    Registry ID
    NCT04576117
    Conditions
    Recurrent Low Grade Astrocytoma; Recurrent WHO Grade 2 Glioma; Refractory Low Grade Astrocytoma; Refractory Low Grade Glioma; Refractory WHO Grade 1 Glioma
    Interventions
    Biospecimen Collection; Magnetic Resonance Imaging; Quality-of-Life Assessment; Questionnaire Administration; Selumetinib Sulfate; Vinblastine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-02-16
    Completion
    2026-12-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Low Grade Astrocytoma; Recurrent WHO Grade 2 Glioma; Refractory Low Grade Astrocytoma; Refractory Low Grade Glioma +1 more
    InterventionBiospecimen Collection; Magnetic Resonance Imaging; Quality-of-Life Assessment; Questionnaire Administration +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

    NCT04383743 · start 2020-11-24

    Registered record
    Registry ID
    NCT04383743
    Conditions
    Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Muscle Invasive Bladder Carcinoma
    Interventions
    Cisplatin; Doxorubicin; Methotrexate; Pegfilgrastim; Pembrolizumab; Radical Cystectomy; Vinblastine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-24
    Completion
    2025-03-04
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Muscle Invasive Bladder Carcinoma
    InterventionCisplatin; Doxorubicin; Methotrexate; Pegfilgrastim +3 more
    PhasePhase 2
    Registry statusCompleted

  • Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

    NCT03907488 · start 2019-08-29

    Registered record
    Registry ID
    NCT03907488
    Conditions
    Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Lymphocyte-Rich Classic Hodgkin Lymphoma
    Interventions
    Biospecimen Collection; Brentuximab Vedotin; Computed Tomography; Dacarbazine; Doxorubicin Hydrochloride; Filgrastim; Magnetic Resonance Imaging; Nivolumab; Pegfilgrastim; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Vinblastine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2019-08-29
    Completion
    2027-03-28
    Enrolment
    994

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnn Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma +6 more
    InterventionBiospecimen Collection; Brentuximab Vedotin; Computed Tomography; Dacarbazine +10 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

    NCT03331341 · start 2019-01-09

    Registered record
    Registry ID
    NCT03331341
    Conditions
    Classical Hodgkin Lymphoma
    Interventions
    Dacarbazine; Doxorubicin Hydrochloride; Laboratory Biomarker Analysis; Pembrolizumab; Vinblastine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-01-09
    Completion
    2023-12-21
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClassical Hodgkin Lymphoma
    InterventionDacarbazine; Doxorubicin Hydrochloride; Laboratory Biomarker Analysis; Pembrolizumab +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

    NCT03755804 · start 2018-12-12

    Registered record
    Registry ID
    NCT03755804
    Conditions
    Hodgkin Lymphoma
    Interventions
    bendamustine; Etoposide; Doxorubicin; Bleomycin; Vincristine; Vinblastine; Prednisone; Filgrastim; Brentuximab Vedotin; Cyclophosphamide; DTIC; Quality of Life Measurements; Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-12-12
    Completion
    2028-07-01
    Enrolment
    232

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma
    Interventionbendamustine; Etoposide; Doxorubicin; Bleomycin +9 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

    NCT03580408 · start 2018-08-31

    Registered record
    Registry ID
    NCT03580408
    Conditions
    Hodgkin Lymphoma; Coexisting Medical Conditions
    Interventions
    Nivolumab; Vinblastin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-08-31
    Completion
    2021-08-12
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma; Coexisting Medical Conditions
    InterventionNivolumab; Vinblastin
    PhasePhase 2
    Registry statusCompleted